# Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

> **NCT03220178** · PHASE4 · TERMINATED · sponsor: **Palleos Healthcare GmbH** · enrollment: 532 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Fulvestrant
- **DRUG:** Anastrozole
- **DRUG:** Letrozole
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT03220178
- **Lead sponsor:** Palleos Healthcare GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-24
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 532 (ACTUAL)
- **Why stopped:** Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220178, "Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03220178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*